A systematic review on disease-drug-drug interactions with immunomodulating drugs
| Autor: | Laura M. de Jong, Sylvia D. Klomp, Nicoline Treijtel, Robert Rissmann, Jesse J. Swen, Martijn L. Manson |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
drug-drug interactions
Interleukin-1beta immunomodulation Risk Assessment Immunomodulating Agents tyrosine kinase inhibitor EMA Humans Drug Interactions Pharmacology (medical) USPI phenoconversion Drug Approval Protein Kinase Inhibitors Drug Labeling Pharmacology therapeutic proteins Interleukin-6 Tumor Necrosis Factor-alpha United States Food and Drug Administration Antibodies Monoclonal disease-drug-drug interactions United States cytokines drug labelling Pharmaceutical Preparations inflammation monoclonal antibody cytochrome P450 enzymes (CYP) SPC FDA |
| Zdroj: | British Journal of Clinical Pharmacology, 88(10), 4387-4402 British Journal of Clinical Pharmacology, 88(10), 4387-4402. WILEY |
| Popis: | Aim: Use of immunomodulating therapeutics for immune-mediated inflammatory diseases may cause disease-drug-drug interactions (DDDIs) by reversing inflammation-driven alterations in the metabolic capacity of cytochrome P450 enzymes. European Medicine Agency (EMA) and US Food and Drug Administration (FDA) guidelines from 2007 recommend that the DDDI potential of therapeutic proteins should be assessed. This systematic analysis aimed to characterize the available DDDI trials with immunomodulatory drugs, experimental evidence for a DDDI risk and reported DDDI risk information in FDA/EMA approved drug labelling. Method: For this systematic review, the EMA list of European Public Assessment Reports of human medicine was used to select immunomodulating monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) marketed after 2007 at risk for a DDDI. Selected drugs were included in PubMed and Embase searches to extract reported interaction studies. The Summary of Product Characteristics (SPCs) and the United States Prescribing Information (USPIs) were subsequently used for analysis of DDDI risk descriptions. Results: Clinical interaction studies to evaluate DDDI risks were performed for 12 of the 24 mAbs (50%) and for none of the TKIs. Four studies identified a DDDI risk, of which three were studies with interleukin-6 (IL-6) neutralizing mAbs. Based on (non)clinical data, a DDDI risk was reported in 32% of the SPCs and in 60% of the USPIs. The EMA/FDA documentation aligned with the DDDI risk potential in 35% of the 20 cases. Conclusion: This systematic review reinforces that the risk for DDDI by immunomodulating drugs is target- and disease-specific. Drug labelling information designates the greatest DDDI risk to mAbs that neutralize the effects of IL-6, Tumor Necrosis Factor alfa (TNF-alpha) and interleukin-1 beta (IL-1 beta) in diseases with systemic inflammation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|